Appointments

Robert J. Bard named COO of molecular fingerprinting company

Published in Cancer Weekly, December 17th, 2002

CeMines, Inc., a privately held company that is developing molecular fingerprinting technology for early detection and treatment of cancer, announced that Robert J. Bard has joined the company as chief operating officer, responsible for all day-to-day operations.

Bard has spent his 28-year career in the medical products industry. Most recently, he served as a corporate officer and the vice president of regulatory affairs at Gliatech, where he was responsible for strategic planning of regulatory affairs, quality assurance, and manufacturing operations.

"As CeMines continues to progress in the clinical development of its molecular fingerprinting...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2002-12-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry